Skip to main content

Thomas Smith

Analyst

Lyric Partners

Equibles does not estimate personal net worth.

About Thomas Smith

Thomas Smith is recorded as Analyst at Lyric Partners. Thomas Smith has spoken on 2 earnings calls and 1 other investor event across 3 companies, most recently for Kyverna Therapeutics, Inc. on September 24, 2026. Those appearances were for Kyverna Therapeutics, Inc. (KYTX), Rhythm Pharmaceuticals, Inc. (RYTM) and Hansa Biopharma AB. The companies whose calls Thomas Smith spoke on are classified in the Healthcare sector.

Thomas Smith on recent calls

“It's always great to see the consistency here as the data continue to mature. Three questions, actually, if I could. First, on the clinical side, in these SDS and MG datasets, nearly all the patients were made off immunosuppressive therapy at one year.”
Analyst — Lyric Partners, Kyverna SPS and MG Longer-term Follow-up Data Conference Call ·
“Thanks for taking our questions and let me add my congrats on the strong quarter and the nice 718 beta here. Just on 718, wondering if you could expand a little bit on the comments regarding the dose escalation in the study, how many of these initial HO patients are getting up to the target dose.”
Analyst — Lyric Partners, Rhythm Pharmaceuticals Q2 2026 Earnings Conference Call ·
“You mentioned that you're actively exploring some additional collaboration opportunities, particularly on the gene therapy side.”
Analyst — Lyric Partners, Interim Report January-June 2026 Conference Call ·

Affiliation history

  • Lyric Partners

    Analyst

    Transcript header (unverified)

    Current

Company network

Hansa Biopharma AB

Biotechnology · Healthcare

1 appearance Latest appearance 2026-07-22

Recent activity